Halozyme Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

78.99 2.56

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78.21

Max

79.36

Pagrindiniai rodikliai

By Trading Economics

Pajamos

292M

150M

Pardavimai

-75M

377M

P/E

Sektoriaus vid.

26.302

56.269

Pelnas, tenkantis vienai akcijai

1.221

Pelno marža

39.832

Darbuotojai

423

EBITDA

-62M

220M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+1.95% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.2B

8.9B

Ankstesnė atidarymo kaina

76.43

Ankstesnė uždarymo kaina

78.99

Naujienos nuotaikos

By Acuity

53%

47%

276 / 342 reitingas Healthcare

Halozyme Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-02 23:41; UTC

News
Social Media

Meta shares rise in after-market trading as CEO Zuckerberg highlights upcoming AI benefits and announces new application Pocket, despite some setbacks.

2026-07-02 23:32; UTC

News
Social Media

Microsoft launches AI initiative Microsoft Frontier Company with $2.5 billion backing. Shares are higher in after-market trading, continuing the broader software sector's upward trend.

2026-07-02 23:31; UTC

News
Social Media
ETF Constituents
Correlated Moves

The Nasdaq 100 Index is higher in after-market hours, buoyed by U.S. jobless data and positive contributions from Microsoft, Meta, and Texas Instruments.

2026-07-02 23:26; UTC

News

O'Reilly Automotive's $10 billion bid for Genuine Parts' division coincides with a decline in shares during after-market trading. Genuine Parts' shares rose significantly.

2026-07-02 23:26; UTC

News

Qualcomm shares are higher in after-market hours despite Elon Musk's denial of a partnership with SpaceX and removal from Russell indexes.

2026-07-02 23:16; UTC

Correlated Moves
News
Macro News
ETF Constituents

Vanguard Information Technology ETF gains after-hours, supported by positive contributions from Microsoft and Texas Instruments, following favorable U.S. jobless data.

2026-07-02 23:16; UTC

News

Microchip Technology Inc shares are higher in after-market trading, despite concerns over AI-driven chip demand and a recent pullback in the Philadelphia Semiconductor Index.

2026-07-02 23:12; UTC

News

Applied Materials shares advanced in after-hours trading, buoyed by positive equity market sentiment and gains in European indices like the DAX.

2026-07-02 23:11; UTC

News
Macro Event
Correlated Moves

The USD/CZK exchange rate is lower today, reflecting recent U.S. labor market data and broader market sentiment influencing currency movements.

2026-07-02 23:11; UTC

Macro Event
News

The USD/PLN exchange rate is lower today, reflecting a decline since Wednesday's close amid mixed U.S. labor market data and unusual volatility.

2026-07-02 23:11; UTC

News
Social Media
Correlated Moves

The EUR/HKD exchange rate is rising, supported by U.S. Dollar weakness after disappointing nonfarm payroll data and positive GBP/USD movements.

2026-07-02 23:11; UTC

News
Macro Event

The U.S. Dollar weakened against the Danish Krone following disappointing June nonfarm payroll data, which showed only 57,000 jobs added.

2026-07-02 23:11; UTC

News
Social Media
Correlated Moves

Weakness in the U.S. Dollar, following disappointing payroll data, supports gains in GBP/HKD during Thursday's session. The asset is higher since Wednesday's close.

2026-07-02 23:11; UTC

News
Macro Event
Correlated Moves

The USD/NOK exchange rate is lower, influenced by weaker U.S. job growth and correlated declines in USD/CAD. Volatility remains notable during Thursday's session.

2026-07-02 23:11; UTC

Correlated Moves
News

Bitcoin remains higher despite SBI Crypto's cessation of mining operations. Earlier in the session, it pulled back from a peak amid significant volatility.

2026-07-02 23:06; UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

2026-07-02 23:06; UTC

Correlated Moves
News

Gold trades slightly higher in after-market hours, supported by a modest rise in silver and tempered rate hike expectations following a weaker jobs report.

2026-07-02 23:01; UTC

Macro Event
News

The USD/ZAR exchange rate is lower today, impacted by weaker U.S. Non-Farm Payrolls data revealing only 57,000 jobs added in June.

2026-07-02 22:51; UTC

Macro Event
News

The Nikkei 225 Index declined in after-market hours, pressured by a sell-off in semiconductor shares and strengthened yen amid government intervention expectations.

2026-07-02 20:13; UTC

ETF Constituents
News

Vanguard Large-Cap ETF declines after market close, influenced by broader market conditions and weaker U.S. jobs data. Holdings like Google and Johnson & Johnson also posted losses.

2026-07-02 20:13; UTC

News
Correlated Moves

The Japanese yen strengthened to a two-week high against the U.S. dollar amid global uncertainties, while Invesco Currencyshares Japanese Yen Trust is trading roughly flat after hours.

2026-07-02 20:07; UTC

Correlated Moves
News
Macro Event

The USD/HUF exchange rate is declining amid disappointing US job growth and a weaker US Dollar Index, with notable intraday volatility.

2026-07-02 20:06; UTC

News

Liberty Global shares are higher as Liberty Latin America is added to several Russell Growth indices, potentially boosting visibility to passive funds and investors.

2026-07-02 20:06; UTC

Correlated Moves
News
Macro Event

The USD/SGD exchange rate is lower today, reflecting pressure from weaker U.S. job growth data and a declining U.S. Dollar Index.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices rise amid weaker U.S. jobs data, which reported only 57,000 new jobs. Easing oil prices and rising silver also support gold's appeal.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher today, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:05; UTC

Correlated Moves
Social Media
ETF Constituents
News

The Communication Services Select Sector SPDR Fund is underperforming, reflecting a decline in the Communications sector. The fund remains roughly flat since Wednesday's close.

2026-07-02 20:05; UTC

News
Social Media

Tesla Inc's stock is declining amid profit-taking despite strong delivery figures. Analysts raised the price target to $430, but investor concerns persist.

Akcijų palyginimas

Kainos pokytis

Halozyme Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

1.95% į viršų

12 mėnesių prognozė

Vidutinis 81 USD  1.95%

Aukščiausias 96 USD

Žemiausias 57 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Halozyme Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

3

Pirkti

2

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

276 / 342 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat